New therapies and prevention strategies for genital herpes

Clinical Infectious Diseases

Volumn 28, Issue 1 SUPPL., 1999, Pages

  Wald, Anna ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; TRIFLURIDINE; VALACICLOVIR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; VERTICAL TRANSMISSION;

EID: 0033041427     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514723     Document Type: Article

References (62)

1. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex type 2 infection in the United States. N Engl J Med 1989; 321: 7-12.
2. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337: 1105-11.
3. Barringer JR. Recovery of herpes simplex virus from human sacral ganglions. N Engl J Med 1974;291:828.
4. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986;314: 144-9.
5. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326:1539-53.
6. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections: the population-based AIDS in Multiethnic Neighborhoods Study. JAMA 1992;268:1700-8.
7. Bernstein D, Lovett M, Bryson Y. Serologic analysis of first episode nonprimary genital herpes simplex virus infection. Am J Med 1984;77: 1055-60.
8. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" HSV-2 infection. Ann Intern Med 1989;110:882-7.
9. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
10. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116: 197-202.
11. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121: 847-54.
12. Ashley R, Cent A, Maggs V, Corey E. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus type 1 and 2. Ann Intern Med 1991;115:520-6.
13. Wald A, Kim M, Catlett L, Selke S, Ashley R, Corey L. Genital HSV-2 shedding in women with HSV-2 antibodies but without a history of genital herpes [abstract no H80]. In: Programs and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
14. Catotti DN, Clarke P, Catoe KE. Herpes revisited: still a cause of concern. Sex Transm Dis 1993;20:77-80.
15. Carney O, Ross E, Ikkos G, Mindel A. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993;69:457-9.
16. Wald A, Benedetti J, Davis G, Remington M, Winter C, Corey L. A randomized, double-blind, comparative trial comparing high and standard dose oral acyclovir for first-episode genital herpes infections. Antimicrob Agents Chemother 1994;38:174-6.
17. Kinghorn GR, Abeywickreme I, Jeavons M, et al. Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes. Genitourin Med 1986;62:186-8.
18. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind randomized clinical trial. Sex Transm Dis 1997;24:481-6.
19. Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir [abstract no 12]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
20. Spruance S, Trying S, Degregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-35.
21. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. Genitourin Med 1997;73:110-6.
22. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996;276:44-9.
23. Patel R, Bodsworth NJ, Wooley P, et al. Valacyclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once-daily therapy. Genitourin Med 1997;73:105-9.
24. Mertz GJ, Loveless MO, Levin MJ, et al. Oral Famciclovir for suppression of recurrent genital herpes simplex vims infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997;157: 343-9.
25. Diaz-Mitoma F, Sibbald RG, Shafran SC, the Collaborative Famciclovir Genital Herpes Suppression Group. Famciclovir suppression of recurrent genital herpes. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
26. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10.
27. Burnette TC, Harrington JA, Reardon JE, Merrill BM, de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 1995; 270:15827-31.
28. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of Valaciclovir, the L-Val ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;36:2759-64.
29. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemo 1993;4(Suppl 1):47-55.
30. Hodge RA, Cheng YC. The mode of action of penciclovir. Antiviral Chem Chemo 1993;4(Suppl 1):13-24.
31. Weinberg A, Bate BJ, Masters HB, et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 1992;36:2037-8.
32. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38:2454-7.
33. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS, the Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex virus following cessation of >6 years of chronic suppression with acyclovir. J Infect Dis 1994;169:1338-41.
34. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993;329:1777-82.
35. Swetter SM, Hill EL, Kern FR, et al. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase deficient herpes simplex virus. J Infect Dis 1998;177:543-50.
36. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995;123:845-7.
37. Pannuti CS, Finck MCDS, Grimbaun RS, et al. Asymptomatic perianal shedding of herpes simplex virus in patients with acquired immunodeficiency syndrome. Arch Dermatol 1997;133:180-3.
38. Schacker T, Hu H, Koelle DM, et al. A double-blind, placebo-controlled trial of famciclovir for the suppression of clinical and subclinical HSV infection in HIV-infected persons. Ann Intern Med 1998;128:21-8.
39. Kessler H, Hurwitz S, Farthing C, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:147-52.
40. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir topical gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex infection in patients with AIDS. J Infect Dis 1997;176:892-8.
41. Gold J, Bell A, the Valaciclovir International HSV Study Group. Valaciclovir prevents herpes simplex virus recurrences in HIV-infected individuals - a double-blind controlled trial [abstract no 4036]. Presented at the 20th International Congress on Chemotherapy (Sydney). 1997.
42. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998; 177:48-56.
43. Chulay JD, Bell AR, Miller GB, the International Valaciclovir HSV Study Group. Long-term safety of valacyclovir for suppression of herpes simplex virus infections. In: Program and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 1996.
44. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994;38: 1246-50.
45. Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990;161: 1078-84.
46. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5.
47. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-6.
48. Mendel DB, Barkhimer DB, Chen MS. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995;39:2120-2.
49. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). Clin Infect Dis 1994;18:570-8.
50. Birch CJ, Tyssen DP, Tachedjian G, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis 1992;166:108-12.
51. Frenkel LM, Brown ZA, Bryson YJ, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 1991; 164:569-76.
52. Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex infections. N Engl J Med 1991;324: 450-4.
53. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
54. Brown ZA, Selke SA, Zeh J, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997;337:509-15.
55. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73.
56. Whaley KJ, Barratt RA, Zeitlin L, Hoen TE, Cone RA. Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J Infect Dis 1993;168:1009-11.
57. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital HSV-2 shedding in immunocompetent women. J Clin Invest 1997;99: 1092-7.
58. Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992;15:1031-8.
59. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984;251:2103-7.
60. Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. The Acyclovir Study Group. JAMA 1991;265: 747-51.
61. Goldberg LH, Kaufman R, Kurtz TO, Conant MA, Eron LI, Batenhorst RI. Long-term suppression of recurrent genital herpes with acyclovir. Arch Dermatol 1993;129:582-7.
62. Corey L, Ashley R, Sekulovich R, et al. Lack of efficacy of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.